About Replicor Inc.

Clearing hepatitis B surface antigen

Replicor is a privately held biopharmaceutical company located in Montreal, Canada. Our novel nucleic acid polymer (NAP) technology has the unique ability to eliminate the viral surface antigen protein in patients with HBV and HDV infection, a key step in achieving functional cure in these patients. NAP-based combination therapy has produced the most advanced animal and human clinical data in th...

Replicor is a privately held biopharmaceutical company located in Montreal, Canada. Our novel nucleic acid polymer (NAP) technology has the unique ability to eliminate the viral surface antigen protein in patients with HBV and HDV infection, a key step in achieving functional cure in these patients. NAP-based combination therapy has produced the most advanced animal and human clinical data in the development of the cure for HBV and HDV infection. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection.

Contact Replicor Inc.

Phone Number
+1 514 733 1998

More About Replicor Inc.

Therapeutic Areas
  • Autoimmune disorders
  • Infectious
Technologies
  • Nucleic acids
Company Type
  • Biotechnology – Therapeutics
State of Ownership
  • Private